Company news
Tetra Bio-Pharma Inc. news in 2020
Tetra Bio-Pharma Inc.'s news releases, calls and decks from 2020, newest first.
Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada
December 29, 2020
Tetra Bio-Pharma Provides Update on Recent Milestones
November 15, 2020
Tetra Bio-Pharma Inc. Acquires Common Shares of Mondias Natural Products Inc.
November 2, 2020
Tetra Bio Pharma Announces Divestiture of Lumiera Health Innovation Inc.
October 27, 2020
IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol
October 21, 2020
Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx
October 20, 2020
Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury
October 19, 2020
Tetra Bio-Pharma to Present at Alpha Bronze Virtual Town Hall
October 5, 2020
Tetra Bio-Pharma (TBP) Acquires Dronabinol Soft Gel Capsules Exclusive Canadian Distribution Rights to Establish a Strong Commercial Presence in Canada and Accelerate its Profitability
September 29, 2020
Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy
September 3, 2020
Tetra Bio-Pharma Announces Plenitude Clinical Trial is Initiated
September 1, 2020
Tetra Bio-Pharma Announces Expected Effective Date of Listing on TSX of its Common Shares and Warrants
July 30, 2020
Tetra Bio-Pharma and Altus Formulation Form New Company "TALLC" to Exploit TA-A001
June 2, 2020
Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA
June 1, 2020
Tetra Bio-Pharma Announces Closing of Public Offering
May 22, 2020
Tetra Bio-Pharma Announces Sizing of Public Offering
May 15, 2020
Tetra Bio-Pharma Announces Overnight Marketed Offering
May 14, 2020
Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program
May 5, 2020
Tetra Receives its 4th FDA Orphan Drug Designation
April 15, 2020
Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program
April 14, 2020
Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License
April 13, 2020
Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions
April 8, 2020
Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011
April 6, 2020
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF
April 2, 2020
Tetra Bio Pharma Announces Filing of Final Base Shelf Prospectus for up to $50 Million of Securities
April 1, 2020
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A
March 30, 2020
Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical Trial
March 26, 2020
Tetra Bio-Pharma Provides Management Update on COVID-19
March 23, 2020
Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and public relations firm
March 6, 2020
Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific
February 27, 2020
Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA
February 25, 2020
Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA
February 24, 2020
Tetra Bio-Pharma Inc. Announces Listing of Warrants
February 20, 2020
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs
February 20, 2020
Tetra Bio-Pharma Appoints Sylvain Chrétien as President
February 18, 2020
Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011
February 13, 2020
Tetra Bio-Pharma Announces Closing of Bought Deal Financing
February 13, 2020
Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™
January 31, 2020
Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003
January 28, 2020
Tetra Bio-Pharma Announces Upsizing of Previously Announced Offering
January 27, 2020
Tetra Bio-Pharma - press release correction
January 22, 2020
Tetra Bio-Pharma Announces $10.0 Million Bought Deal Offering
January 21, 2020
Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs
January 20, 2020
Tetra Bio-Pharma Granted Two OTC Drug Identification Numbers (DIN) by Health Canada
January 17, 2020
Tetra Bio-Pharma Receives Favorable Letter of Advice from USA FDA for QIXLEEF
January 13, 2020